


CLAIMS


1. A compound of formula (I):



(I)

wherein:

- 5 R¹ represents hydrogen, C₁₋₄alkyl, -CH₂CO₂H, -CH₂CO₂C₁₋₂alkyl, or -CH₂CONR⁷R⁸;
- R² and R³ independently represent hydrogen, -C₁₋₆alkyl, -C₁₋₃alkylCN, -C₁₋₃alkylCO₂H, -C₁₋₄alkylOC₁₋₄alkyl, -C₁₋₄alkylS(O)_nC₁₋₄alkyl, -C₁₋₄alkylNR¹⁰R¹¹, -C₁₋₃alkylNCO₂C₁₋₄alkyl, -C₁₋₃alkylCONR⁷R⁸, -C₁₋₃alkylCO₂C₀₋₂alkylR⁹, -C₁₋₃alkylCO₂alkylR⁹, -C₁₋₃alkylCON(R⁸)C₀₋₂alkylR⁹, -C₁₋₃alkylNCO₂C₀₋₂alkylR⁹, -C₁₋₃alkylNCO₂alkylR⁹ or -C₀₋₂alkylR⁹, with the proviso that one of R² and R³ is hydrogen and the other is a substituent other than hydrogen;
- 10 n is an integer between 0 and 2;
- R⁴ and R⁵ together with the nitrogen atom to which they are attached form a morpholino ring;
- 15 R⁶ represents a group selected from:



Wherein T_1 and T_2 independently represent CH_2 , NH , S or O with the proviso that when one of T_1 or T_2 represents NH , S or O the other represents CH_2 ;

M represents CH_3 , $-OH$ or $=O$;

V represents CH or N ;

5 W represents H , CH_3 , Cl or F ;

X represents Cl , Br , F or $-CH_3$;

Y represents CH_3 or CF_3 ;

Z represents $-CH_3$ or F ;

10 R^7 and R^8 are independently hydrogen, C_{1-4} alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O , N or S ;

R^{10} and R^{11} independently represent C_{1-4} alkyl or together with the N atom to which they are bonded form a 5- or 6- membered non-aromatic heterocyclic ring, optionally containing an additional heteroatom selected from O , N or S ;

15 R^9 represents phenyl or a 5- or 6- membered aromatic or non-aromatic heterocyclic group, containing at least one heteroatom selected from O , N or S , each of which is optionally substituted by 0-2 groups selected from: C_{1-3} alkyl or halogen; and pharmaceutically acceptable derivatives thereof.

20 2. A compound of formula (I) as claimed in claim 1 wherein R^1 represents hydrogen, methyl, $-CH_2CO_2C_{1-2}$ alkyl, or $-CH_2CONR^7R^8$.

25 3. A compound of formula (I) as claims in claim 1 or claim 2 wherein R^2 and R^3 independently represent $-C_{1-6}$ alkyl, $-C_{1-3}$ alkylCN, $-C_{1-4}$ alkylOC $_1$ alkyl, $-C_{1-4}$ alkylS(O) $_n$ C $_1$ alkyl, $-C_{1-4}$ alkylNR 10 R 11 , $-C_{1-3}$ alkylCONR $^7R^8$, $-C_{1-3}$ alkylCO $_2$ C $_{0-2}$ alkylR 9 ,


$-C_{1-3}\text{alkylCON}(R^8)C_{0-2}\text{alkyl}R^9$ or $-C_{0-2}\text{alkyl}R^9$, with the proviso that one of R^2 and R^3 is hydrogen and the other is a substituent other than hydrogen.

4. A compound of formula (I) as claimed in any of claims 1-3 wherein R^3 represents

5 hydrogen.

5. A compound of formula (I) as claimed in any of claims 1-4 wherein R^6 represents a group selected from:

10



6. A compound as claimed in claim 1 wherein:


R^1 represents hydrogen, methyl, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{CH}_2\text{CO}_2\text{C}_{1-2}\text{alkyl}$, or $-\text{CH}_2\text{CONR}^7\text{R}^8$;

15 R^2 represents $-C_{1-4}\text{alkyl}$, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}(\text{CH}_3)\text{OCH}_3$, $-\text{CH}_2\text{CON}(\text{CH}_3)_2$, benzyl, $-\text{CH}_2\text{CO}_2\text{-benzyl}$, $-\text{CH}_2\text{CO}\text{-morpholine}$, or $-\text{CH}_2\text{-thiophene}$;

R^3 represents hydrogen;

R^4 and R^5 together with the nitrogen atom to which they are attached form a morpholino ring;

20 R^6 represents a group selected from:



wherein W represents H, Cl or F;

X represents Cl, Br, F or -CH₃;

Y represents CH₃ or CF₃;

Z represents -CH₃ or F;

R⁷ and R⁸ are independently hydrogen or methyl.

5

7. A compound according to any of claims 1-6 for use in therapy.

8. A pharmaceutical composition comprising a compound according to any of claims 1-6 together with a pharmaceutical carrier and/or excipient.

10



9. Use of a compound according to any of claims 1-6 for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to amelioration by a thrombin inhibitor.

15

10. A method of treating a patient suffering from a condition susceptible to amelioration by a thrombin inhibitor comprising administering a therapeutically effective amount of a compound according to any of claims 1-6.

20

11. A process for preparing a compound of formula (I) which comprises reacting a compound of formula (II) with a compound of formula (III):



25

30